WO2008021483A3 - Procédé de pronostic et diagnostic pour la thérapie d'une maladie - Google Patents

Procédé de pronostic et diagnostic pour la thérapie d'une maladie Download PDF

Info

Publication number
WO2008021483A3
WO2008021483A3 PCT/US2007/018233 US2007018233W WO2008021483A3 WO 2008021483 A3 WO2008021483 A3 WO 2008021483A3 US 2007018233 W US2007018233 W US 2007018233W WO 2008021483 A3 WO2008021483 A3 WO 2008021483A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
therapy
markers
pathway
cancers
Prior art date
Application number
PCT/US2007/018233
Other languages
English (en)
Other versions
WO2008021483A2 (fr
Inventor
Gennadi V Glinksy
Original Assignee
Ordway Res Inst
Gennadi V Glinksy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2007/008088 external-priority patent/WO2007114896A2/fr
Application filed by Ordway Res Inst, Gennadi V Glinksy filed Critical Ordway Res Inst
Priority to CA002660857A priority Critical patent/CA2660857A1/fr
Priority to EP07836975A priority patent/EP2059615A2/fr
Publication of WO2008021483A2 publication Critical patent/WO2008021483A2/fr
Publication of WO2008021483A3 publication Critical patent/WO2008021483A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)

Abstract

La présente invention concerne de nouveaux procédés et nécessaires pour diagnostiquer la présence de cancer chez u patient, et pour déterminer si un sujet cancéreux est capable de réagir à différents types de schémas thérapeutiques. Les cancers à tester sont notamment ceux de la prostate, des seins, des poumons, de l'estomac, des ovaires, de la vessie, les lymphomes, les mésothéliomes, les médulloblastomes, les gliomes et la leucémie myéloïde aigüe (AML). L'identification de patients résistant à la thérapie au début de leur schéma thérapeutique peut conduire à une modification de la thérapie de façon à obtenir une issue plus favorable. Un mode de réalisation de l'invention concerne un procédé de diagnostic de cancer ou de prédiction d'issue de thérapie anticancéreuse par détection des niveaux d'expression de plusieurs marqueurs dans la même cellule au même moment, et par notation de leur expression comme se situant au-dessus d'un certain seuil, les marqueurs provenant d'une voie particulière se rapportant au cancer, la note étant une indication ou un diagnostic de cancer, ou un pronostic d'échec de thérapie anticancéreuse. Ce procédé convient pour le diagnostic du cancer ou la prédiction des issues des traitements anticancéreux pour divers cancers. Les marqueurs peuvent provenir de n'importe quelle voie impliquée dans la régulation du cancer, et notamment spécifiquement de la voie PcG et de la voie de 'souchitude' au sens de 'caractéristique des cellules souches'. Les marqueurs peuvent être de l'ARNm, de l'ARNmicro, de l'ADN, ou de la protéine.
PCT/US2007/018233 2006-08-17 2007-08-17 Procédé de pronostic et diagnostic pour la thérapie d'une maladie WO2008021483A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002660857A CA2660857A1 (fr) 2006-08-17 2007-08-17 Procede de pronostic et diagnostic pour la therapie d'une maladie
EP07836975A EP2059615A2 (fr) 2006-08-17 2007-08-17 Procédé de pronostic et diagnostic pour la thérapie d'une maladie

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US82270506P 2006-08-17 2006-08-17
US60/822,705 2006-08-17
US82357706P 2006-08-25 2006-08-25
US60/823,577 2006-08-25
US87506106P 2006-12-15 2006-12-15
US60/875,061 2006-12-15
PCT/US2007/008088 WO2007114896A2 (fr) 2006-03-31 2007-04-02 Procédé de pronostic et de diagnostic destiné à une cancérothérapie
US11/732,442 2007-04-02
US11/732,442 US7890267B2 (en) 2006-03-31 2007-04-02 Prognostic and diagnostic method for cancer therapy
USPCT/US2007/008088 2007-04-02
US92234007P 2007-04-05 2007-04-05
US60/922,340 2007-04-05

Publications (2)

Publication Number Publication Date
WO2008021483A2 WO2008021483A2 (fr) 2008-02-21
WO2008021483A3 true WO2008021483A3 (fr) 2009-03-26

Family

ID=56291006

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/018233 WO2008021483A2 (fr) 2006-08-17 2007-08-17 Procédé de pronostic et diagnostic pour la thérapie d'une maladie

Country Status (3)

Country Link
EP (1) EP2059615A2 (fr)
CA (1) CA2660857A1 (fr)
WO (1) WO2008021483A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7897356B2 (en) 2008-11-12 2011-03-01 Caris Life Sciences Methods and systems of using exosomes for determining phenotypes
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114896A2 (fr) * 2006-03-31 2007-10-11 Ordway Research Institute Procédé de pronostic et de diagnostic destiné à une cancérothérapie
WO2009136867A1 (fr) 2008-05-06 2009-11-12 Agency For Science, Technology And Research Procédé de réalisation de la dédifférenciation d’une cellule
CN101792793B (zh) * 2009-10-26 2012-05-23 中南大学 miR-182作为胶质瘤发生分子标志物的应用及其检测试剂盒
JP5808349B2 (ja) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー セラノーシスのためのバイオマーカー
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
WO2012135651A1 (fr) 2011-03-31 2012-10-04 The Procter & Gamble Company Systèmes, modèles et méthodes pour identifier et évaluer des agents dermatologiques servant à traiter les pellicules et la dermatite séborrhéique
EP2726869B1 (fr) * 2011-06-29 2017-08-09 Duke University Mutations somatiques de l'atrx dans le cancer du cerveau
JP2015501138A (ja) 2011-10-07 2015-01-15 ユニヴェルシテ モンペリエ ドゥ シアンス エ テクニックＵｎｉｖｅｒｓｉｔｅ Ｍｏｎｔｐｅｌｌｉｅｒ ２ Ｓｃｉｅｎｃｅｓ Ｅｔ Ｔｅｃｈｎｉｑｕｅｓ 神経膠腫の予後予測
US9920357B2 (en) 2012-06-06 2018-03-20 The Procter & Gamble Company Systems and methods for identifying cosmetic agents for hair/scalp care compositions
US9615269B2 (en) 2014-10-02 2017-04-04 At&T Intellectual Property I, L.P. Method and apparatus that provides fault tolerance in a communication network
US9871283B2 (en) 2015-07-23 2018-01-16 At&T Intellectual Property I, Lp Transmission medium having a dielectric core comprised of plural members connected by a ball and socket configuration
EP3674421A1 (fr) * 2018-12-28 2020-07-01 Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE Procédés de pronostic du cancer de la prostate
CN115116550A (zh) * 2022-06-08 2022-09-27 中国科学院苏州生物医学工程技术研究所 疾病预后模型的制作方法、预测方法、装置、介质

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011625A2 (fr) * 2002-07-31 2004-02-05 University Of Southern California Polymorphismes de prediction de maladies et resultat therapeutique
US20060073479A1 (en) * 2001-11-28 2006-04-06 Frudakis Tony N Single nucleotide polymorphisms and combinations thereof predictive for paclitaxel responsiveness

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060073479A1 (en) * 2001-11-28 2006-04-06 Frudakis Tony N Single nucleotide polymorphisms and combinations thereof predictive for paclitaxel responsiveness
WO2004011625A2 (fr) * 2002-07-31 2004-02-05 University Of Southern California Polymorphismes de prediction de maladies et resultat therapeutique

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AFFYMETRIX: "GeneChip Human genome U95 Set", DATA SHEET, 2003, XP002504985, Retrieved from the Internet <URL:http://www.affymetrix.com/support/technical/datasheets/hgu95_datasheet.pdf> *
CHEUNG VIVIAN G ET AL: "Mapping determinants of human gene expression by regional and genome-wide association", NATURE (LONDON), vol. 437, no. 7063, October 2005 (2005-10-01), pages 1365 - 1369, XP002504984, ISSN: 0028-0836 *
GLINSKY G V ET AL: "Gene expression profiling predicts clinical outcome of prostate cancer", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 113, no. 6, 1 March 2004 (2004-03-01), pages 913 - 923, XP002395330, ISSN: 0021-9738 *
GLINSKY GENNADI V ET AL: "Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 115, no. 6, 1 June 2005 (2005-06-01), pages 1503 - 1521, XP002460132, ISSN: 0021-9738 *
IMAI YASUO ET AL: "C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION OF CANCER RESEARCH, US, vol. 1, no. 8, 17 June 2002 (2002-06-17), pages 611 - 616, XP002256816, ISSN: 1535-7163 *
SPIELMAN RICHARD S ET AL: "Common genetic variants account for differences in gene expression among ethnic groups", NATURE GENETICS, vol. 39, no. 2, February 2007 (2007-02-01), pages 226 - 231, XP002504983, ISSN: 1061-4036 *
VARAMBALLY S ET AL: "Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression", CANCER CELL, CELL PRESS, US, vol. 8, no. 5, 14 November 2005 (2005-11-14), pages 393 - 406, XP002395335, ISSN: 1535-6108 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
US7897356B2 (en) 2008-11-12 2011-03-01 Caris Life Sciences Methods and systems of using exosomes for determining phenotypes
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors

Also Published As

Publication number Publication date
WO2008021483A2 (fr) 2008-02-21
EP2059615A2 (fr) 2009-05-20
CA2660857A1 (fr) 2008-02-21

Similar Documents

Publication Publication Date Title
WO2007114896A3 (fr) Procédé de pronostic et de diagnostic destiné à une cancérothérapie
WO2008076447A3 (fr) Traitements de maladies résistantes aux thérapies et combinaisons médicamenteuses pour traiter celles-ci
WO2008021483A3 (fr) Procédé de pronostic et diagnostic pour la thérapie d&#39;une maladie
EP2788752B1 (fr) Procédé de sélection d&#39;un traitement destiné à des patients souffrant d&#39;un cancer du poumon
WO2006085684A3 (fr) Methode de diagnostic du cancer de la vessie
Labidi et al. Predicting success of endoscopic third ventriculostomy: validation of the ETV Success Score in a mixed population of adult and pediatric patients
WO2009103790A3 (fr) Procédé et trousse de détection des gènes associés à la mutation du pik3ca et impliqués dans l’activation de la voie pi3k/akt dans les sous-types er-positifs et her2-positifs avec des implications cliniques.
WO2005028676A3 (fr) Methode de diagnostic du cancer du sein
WO2002061128A3 (fr) Procede permettant de determiner un regime chimiotherapeutique base sur l&#39;expression ercc1
WO2007013665A3 (fr) Methode permettant de diagnostiquer un cancer du poumon a petites cellules
CA2749817A1 (fr) Procedes de determination d&#39;une reponse de patient par la mesure de l&#39;expression de her-2
MXPA06014175A (es) Diagnostico o pronostico del curso del cancer de mama.
US20200332363A1 (en) Methods for predicting risk of recurrence and/or metastasis in soft tissue sarcoma
CN106662543A (zh) 肺癌患者中的非侵入性基因突变检测
Li et al. Prognostic role of epidermal growth factor-like domain 7 protein expression in laryngeal squamous cell carcinoma
CN108728535A (zh) hsa_circ_0049154作为***癌分子靶标在制备药物和试剂盒中的应用
WO2012044696A3 (fr) Prédiction de résultats cliniques dans des malignités hématologiques au moyen d&#39;une signature de l&#39;expression d&#39;auto-renouvellement
TW200643176A (en) ZNFN3A1/breast cancer related gene ZNFN3A1
JP2013532489A (ja) 遺伝子発現プロファイリングに基づくがん治療への応答の予測ならびにモニタリング
JP2013532489A5 (fr)
ES2882875T3 (es) Método de pronóstico y predicción de la recurrencia del cáncer de mama, marcadores empleados en el mismo y kit del mismo
CN105154447B (zh) Ac016745.3作为***癌分子靶标及其在诊断试剂盒中的应用
US20140371081A1 (en) Compositions for and Methods of Detecting, Diagnosing, and Prognosing Thymic Cancer
Sienko et al. Peroxiredoxin-1 as a prognostic factor in patients with ovarian cancer
SG163614A1 (en) Colon cancer related gene tom34

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07836975

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2660857

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007836975

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU